Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 80

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 80
---
 the following:

| ● | 8,188,742 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $14.49 per share; |

| ● | 509,133 shares of common stock underlying outstanding options of the Company, with a weighted average exercise price of $4.75 per share; |

| ● | 560,171 shares of common stock issuable upon conversion of the 1,039 shares of the Company’s Series A Preferred Stock outstanding, at a conversion price equal to $2.25 per share; and |

| ● | 2,158,658 shares of common stock reserved for issuance under the Plan. |

46

The discussion and table above assume the full exercise of the Pre-Funded Warrants included in the pre-funded Units and no exercise of the Series Warrants.

To the extent that our outstanding options or warrants are exercised, new options or RSUs are issued under our equity incentive plan, or additional shares of our common stock are issued in the future, there may be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

<div align='center'>47</div>

### UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Metuchen Pharmaceuticals LLC (“Metuchen”), a wholly owned subsidiary of the Company, previously entered into that certain (a) Settlement Agreement (the “Settlement Agreement”) and Security Agreement (the “Security Agreement”), each dated January 18, 2022, with Vivus LLC (“Vivus”) and (b) a Promissory Note dated January 18, 2022, payable to the order of Vivus (the “Promissory Note”). As a result of an event of default under the Settlement Agreement and the Security Agreement existing and continuing by virtue of Metuchen’s failure to pay the Installment (as defined in the Promissory Note) that was due October 1, 2024 (the “Vivus Event of Default”), all the obligations of Metuchen under the Settlement Agreement and the Security Agreement (the “Obligations”) became immediately due and payable on the date of the Foreclosure Notice (as